期刊
SCIENCE
卷 296, 期 5567, 页码 545-547出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1068274
关键词
-
资金
- NIAID NIH HHS [AI40956, AI26912, R01 AI026912] Funding Source: Medline
For half a century, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to host-parasite differences in drug binding to dihydrofolate reductase-thymidylate synthase (DHFR-TS). Selectivity may also arise through previously unappreciated differences in regulation of this drug target. The DHFR-TS of Plasmodium binds its cognate messenger RNA (mRNA) and inhibits its own translation. However, unlike translational regulation of DHFR or TS in humans, DHFR-TS mRNA binding is not coupled to enzyme active sites. Thus, antifolate treatment does not relieve translational inhibition and parasites cannot replenish dead enzyme.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据